Product Detailed Description

Liposomal gastrodin 70% — High Bioavailability Neuroprotective Supplement

Product Overview

liposomal Gastrodin 70% is a premium-grade dietary supplement ingredient delivering gastrodin in an advanced liposomal delivery system. Gastrodin (CAS 62499-27-8), also known as 4-(hydroxymethyl)phenyl-beta-D-glucopyranoside or gastrodine, is the major active constituent of Gastrodia elata Blume (Orchidaceae), a medicinal plant commonly known as Tianma in China. It is a phenolic glycoside that is chemically characterized by a glucose unit conjugated to a 4-hydroxybenzyl alcohol moiety via a β-glycosidic linkage. Gastrodin occurs as white to almost white powder or crystals and is soluble in water and methanol.

Gastrodia elata has been used for centuries in traditional Chinese medicine for the treatment of infantile convulsion, epilepsy, spasm, tetanus, and vertigo. Gastrodin has been reported to possess a wide range of pharmacological effects, including antioxidation, anti-inflammation, hypoglycemic, hypolipidemic, antitumor, immunomodulation, and antiallergy activities, as well as good sedative and sleep-inducing effects that can alleviate symptoms of neurasthenia, insomnia, and headache. It is clinically used for brain-related diseases in China and has shown promise as a therapeutic agent for demyelinating diseases.

Why Liposomal Technology?

Conventional gastrodin presents significant formulation and bioavailability challenges. Gastrodin is a water-soluble drug with limited passive permeability across biological membranes, and its ability to cross the blood-brain barrier is restricted. This limits its therapeutic potential for central nervous system (CNS) disorders despite its established neuroprotective properties.

Liposomal encapsulation provides four critical advantages:

1. Dramatically Enhanced Brain Delivery — A multivesicular liposome formulation of gastrodin (GAS-MVLs), prepared by microfluidic technology, achieved an average particle size of 2.09 ± 0.17 μm with a dense, spherical structure and relatively narrow size distribution. In vivo pharmacokinetic studies in mice demonstrated that the intracerebral AUC of GAS-MVLs was 5.68 times higher than that of the GAS solution, with a Cmax 2.036 times higher. The brain-targeting efficiency (BTE) was 1.945, and the relative uptake rate (Re) was 5.688, indicating significant enrichment of gastrodin in the brain.

2. Enhanced Blood-Brain Barrier Permeability — In an in vitro BBB model established by coculturing mouse brain endothelial cells (bEnd.3) and astrocytes (C8-D1A), the apparent transmittance of GAS-MVLs was 67.71% at 6 hours after administration, which was 1.92 times higher than that of the GAS solution.

3. Protection from Degradation and Premature Metabolism — The phospholipid bilayer shields gastrodin from enzymatic degradation and premature metabolism during digestive transit, preserving its intact molecular structure until reaching optimal absorption sites.

4. Sustained Release for Prolonged Neuroprotective Activity — Liposomal delivery provides a controlled-release profile that maintains steady plasma levels of gastrodin, supporting prolonged neuroprotective and neuromodulatory activity rather than a sharp peak followed by rapid clearance.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% gastrodin by HPLC, with ≥98.0% (HPLC) assay available for premium applications.

• Liposomal Enhancement — Multivesicular liposome encapsulation achieves 5.68-fold higher intracerebral AUC and 2.036-fold higher Cmax compared to free gastrodin solution, with 1.92-fold higher BBB permeability.

• Clinically Established for Neurological Disorders — Gastrodia elata has been used to treat infantile convulsion, epilepsy, spasm, tetanus, and vertigo. Gastrodin is clinically used for brain-related diseases in China.

• Neuroprotective Mechanisms — Gastrodin demonstrates significant neuroprotective effects across various neurodegenerative disease models, including Alzheimer's disease and Parkinson's disease. Its mechanisms involve multi-target actions such as inhibiting pathological protein aggregation (Aβ) and modulating oxidative stress, ferroptosis, and cellular senescence.

• Demyelinating Disease Support — Gastrodin promotes CNS myelinogenesis and alleviates demyelinating injury by activating the PI3K/AKT/mTOR signaling pathway, identifying it as a promising therapeutic agent for demyelinating diseases.

• Sedative and Sleep Support — Gastrodin exhibits good sedative and sleep-inducing effects and can alleviate symptoms of neurasthenia, insomnia, and headache.

• Brain-Targeting Ligand — Gastrodin has been explored as a brain-targeting ligand for the construction of novel glucose transporter (GLUT1)-targeted lipid drug delivery systems, demonstrating favorable targeting to bEnd.3 brain microvascular endothelial cells and GL glioma cells.

• Water-Dispersible — Liposomal powder offers excellent dispersibility in aqueous systems; suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies and commercial products commonly recommend varying doses of gastrodin depending on the application. For oral tablets, the typical dosage is 50–100 mg per administration, taken three times daily (150–300 mg/day). For maximum neuroprotective benefit, a suggested regimen of 600 mg gastrodin in divided doses (300 mg twice daily) for thirty days has been reported, followed by a maintenance dose of 300 mg daily based on the experience of gastrodin as an over-the-counter pharmaceutical agent. For injection, 0.6 g once daily for 14 days has been used in clinical studies for cerebral infarction. For sustained-release tablets, 150 mg twice daily for 4 weeks has been evaluated. For general neuroprotective and cognitive support, 300–600 mg daily in divided doses is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability and brain targeting.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.